Roche reported positive phase 3 results for sefaxersen in IgA nephropathy, a move that could increase competitive pressure in a market now crowded with multiple approved therapies. The company said the data met phase 3 endpoints in the Imagination study and positions sefaxersen for an accelerated FDA filing. Sefaxersen, previously known as IONIS-FB-LRx, is self-administered as a once-monthly injection and is designed as an mRNA-targeted therapy for a progressive autoimmune kidney disease. Analysts highlighted that a potential approval would expand options for patients whose disease continues despite existing standards. For developers, the readout underscores a broader shift in kidney care toward targeted molecular therapies with differentiated dosing schedules—where payer adoption may hinge on durability, safety profiles and real-world proteinuria outcomes.